Alain H. Rook

Alain H. Rook's AcademicInfluence.com Rankings

Alain H. Rook

Biology

#12776

World Rank

#16274

Historical Rank

Immunology

#859

World Rank

#882

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Alain H. Rook Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alain H. Rook's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. (1983) (1580)
Acquired Immunodeficiency Syndrome: Epidemiologic, Clinical, Immunologic, and Therapeutic Considerations (1984) (786)
Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. (2010) (576)
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. (1986) (570)
Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. (1982) (556)
Immunopathogenesis and therapy of cutaneous T cell lymphoma. (2005) (411)
Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. (1983) (384)
Herpesvirus infections in the acquired immune deficiency syndrome. (1984) (383)
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. (2018) (330)
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. (2015) (283)
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. (1992) (276)
Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: relevance to mechanism of therapeutic action. (1996) (273)
Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. (1999) (269)
Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. (1994) (249)
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. (1996) (238)
Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. (1992) (237)
Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2 (2015) (229)
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. (1992) (228)
Classification and Prediction of Survival in Patients with the Leukemic Phase of Cutaneous T Cell Lymphoma (2003) (192)
IL-12 synthesis by human Langerhans cells. (1996) (188)
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. (1996) (187)
Extracorporeal photochemotherapy induces the production of tumor necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. (1992) (166)
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. (2015) (160)
Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). (2011) (160)
Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells. (1987) (153)
Extracorporeal photochemotherapy for drug-resistant pemphigus vulgaris. (1990) (151)
Photopheresis: clinical applications and mechanism of action. (1999) (146)
TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma (2013) (141)
Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. (2013) (139)
IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. (1995) (136)
Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. (1984) (132)
Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. (2010) (128)
Regulation of cytokine expression in macrophages and the Langerhans cell‐like line XS52 by calcitonin gene‐related peptide (1997) (122)
Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. (1986) (122)
A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. (2006) (119)
Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. (2001) (117)
Extracorporeal photopheresis: past, present, and future. (2009) (116)
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study. (2020) (112)
The immunopathogenesis of cutaneous T-cell lymphoma. (1995) (112)
HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. (1984) (111)
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project (2014) (110)
IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. (2013) (109)
Calcitonin Gene-Related Peptide Inhibits Proliferation and Antigen Presentation by Human Peripheral Blood Mononuclear Cells: Effects on B7, Interleukin 10, and Interleukin12 (1997) (106)
Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. (1985) (102)
The immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine production by Sézary T cells. (1993) (100)
Interactions of cytomegalovirus with the human immune system. (1988) (99)
Death in the AIDS patient: role of cytomegalovirus. (1983) (98)
Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. (2004) (91)
HLA-restricted cytotoxic T lymphocyte and nonthymic cytotoxic lymphocyte responses to cytomegalovirus infection of bone marrow transplant recipients. (1981) (90)
Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod. (2002) (89)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium (2017) (87)
Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to 99% circulating tumor cells with 90% accuracy. (2006) (87)
Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. (2010) (87)
Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism. (1985) (87)
Combined therapy for Sézary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations. (1991) (84)
Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. (1999) (84)
Red cell autoantibodies in patients with acquired immune deficiency syndrome (1986) (82)
Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. (2008) (82)
Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. (1997) (81)
Chlamydiapneumoniae Inhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-101 (2000) (78)
Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin. (2016) (78)
Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. (2002) (75)
Calcitonin gene-related peptide inhibits proliferation and antigen presentation by human peripheral blood mononuclear cells: effects on B7, interleukin 10, and interleukin 12. (1997) (72)
Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. (2001) (71)
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression. (2008) (71)
Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. (1998) (71)
Reduced surface expression of transforming growth factor beta receptor type II in mitogen-activated T cells from Sézary patients. (1995) (71)
Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. (1984) (70)
Molecular diagnosis of cutaneous T-cell lymphoma: polymerase chain reaction amplification of T-cell antigen receptor beta-chain gene rearrangements. (1991) (70)
Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study (2016) (69)
A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. (2010) (69)
Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-cell Lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas (2017) (68)
Partial immune reconstitution in a patient with the acquired immunodeficiency syndrome. (1984) (67)
Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12. (2001) (66)
A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. (2006) (64)
Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. (2010) (63)
Biological effects of bexarotene in cutaneous T-cell lymphoma. (2005) (63)
Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. (2015) (62)
Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and allograft rejection. (1994) (61)
NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations. (1984) (60)
Deficient ?-interferon production in patients with systemic lupus erythematosus (1986) (59)
Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: An effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. (2003) (59)
Eosinophilic fasciitis and eosinophilic cellulitis in a patient with abnormal circulating clonal T cells: increased production of interleukin 5 and inhibition by interferon alfa. (2003) (59)
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patients (2012) (58)
γc-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes1 (2008) (58)
Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression. (1998) (58)
The Role for Interleukin‐12 Therapy of Cutaneous T Cell Lymphoma (2001) (56)
Depressed IL-12-mediated signal transduction in T cells from patients with Sézary syndrome is associated with the absence of IL-12 receptor beta 2 mRNA and highly reduced levels of STAT4. (1999) (55)
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. (2004) (54)
L-tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. (1990) (53)
Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma (2014) (52)
Simultaneous Inhibition of mTOR-Containing Complex 1 (mTORC1) and MNK Induces Apoptosis of Cutaneous T-Cell Lymphoma (CTCL) Cells (2011) (51)
Use of interleukin-2 in patients with acquired immunodeficiency syndrome. (1984) (51)
Interferon-related leukocyte inclusions in acquired immune deficiency syndrome: localization in T cells. (1984) (51)
Bexarotene blunts malignant T‐cell chemotaxis in Sezary syndrome: Reduction of chemokine receptor 4‐positive lymphocytes and decreased chemotaxis to thymus and activation‐regulated chemokine (2007) (51)
Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. (1999) (51)
MALIGNANCIES IN THE AIDS PATIENT: NATURAL HISTORY, TREATMENT STRATEGIES, AND PRELIMINARY RESULTS (1984) (51)
Large-cell transformation following detection of minimal residual disease in cutaneous T-cell lymphoma: molecular and in situ analysis of a single neoplastic T-cell clone expressing the identical T-cell receptor. (1995) (50)
Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. (1991) (50)
Update on treatment of cutaneous T-cell lymphoma (2009) (49)
Mycosis fungoides and sezary syndrome: An update (2006) (49)
Treatment of autoimmune disease with extracorporeal photochemotherapy: progressive systemic sclerosis. (1989) (48)
The clonal nature of circulating Sezary cells. (1995) (47)
Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. (2003) (45)
Reversal of acute renal allograft rejection by extracorporeal photopheresis: A case presentation and review of the literature (1996) (45)
A role for regulatory T cells in cutaneous T-Cell lymphoma; induction of a CD4 + CD25 + Foxp3+ T-cell phenotype associated with HTLV-1 infection. (2006) (43)
Chlamydia pneumoniaeInhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-10 (2000) (43)
The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. (2015) (43)
Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. (2001) (42)
Molecular diagnosis of lymphocytic infiltrates of the skin. (1993) (40)
The Potential Therapeutic Role of Interleukin‐12 in Cutaneous T‐Cell Lymphoma a (1996) (40)
Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. (2001) (40)
Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. (2008) (39)
Failure to detect human T-lymphotropic virus type-I proviral DNA in cell lines and tissues from patients with cutaneous T-cell lymphoma. (1996) (39)
High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response. (2011) (38)
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sézary syndrome: circumvention by hexameric soluble CD40L. (2005) (38)
Complete remission in advanced blastic NK‐cell lymphoma/leukemia in elderly patients using the hyper‐CVAD regimen (2003) (36)
Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. (2002) (36)
Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma. (2019) (36)
CD164 and FCRL3 are highly expressed on CD4+CD26-T cells in Sézary syndrome patients (2013) (36)
ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. (2016) (36)
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin (2013) (35)
Selective defects in cytomegalovirus- and mitogen-induced lymphocyte proliferation and interferon release in patients with acquired immunodeficiency syndrome. (1985) (35)
Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome. (2008) (34)
Deficient, HLA-restricted, cytomegalovirus-specific cytotoxic T cells and natural killer cells in patients with the acquired immunodeficiency syndrome. (1985) (33)
High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome. (2006) (32)
ROLE OF INTERFERON IN AIDS a (1984) (32)
The sign of Leser-Trélat in association with Sézary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa. (1993) (31)
Therapeutic applications of photopheresis. (1993) (30)
Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma (2011) (30)
Treatment of autoimmune disease with extracorporeal photochemotherapy: pemphigus vulgaris--preliminary report. (1989) (30)
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. (2002) (30)
Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. (2007) (29)
De novo development of psoriatic plaques in patients receiving interferon alfa for treatment of erythrodermic cutaneous T-cell lymphoma. (1995) (28)
A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome. (2009) (28)
Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing. (2006) (27)
Stem cell transplantation in advanced cutaneous T-cell lymphoma. (2008) (27)
Successful reversal of severe refractory cardiac allograft rejection by photopheresis. (2001) (26)
Th2 cytokine profile in cutaneous T-cell lymphoma. (1995) (26)
In vivo imaging of cutaneous T-cell lymphoma migration to the skin. (2009) (26)
Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome. (2012) (26)
Effectiveness of photopheresis in Sézary syndrome. (1999) (25)
Interferon-induced 2'-5' oligoadenylate synthetase during interferon-alpha therapy in homosexual men with Kaposi's sarcoma: marked deficiency in biochemical response to interferon in patients with acquired immunodeficiency syndrome. (1985) (25)
Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. (1997) (25)
Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome. (2005) (25)
Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study (2008) (25)
The pathogenesis of large cell transformation in cutaneous T‐cell lymphoma is not associated with t(2;5)(p23;q35) chromosomal translocation (1997) (25)
Successful reversal of recalcitrant hepatic allograft rejection by photopheresis (2000) (24)
Lethal vascular leak syndrome after denileukin diftitox administration to a patient with cutaneous gamma/delta T‐cell lymphoma and occult cirrhosis (2008) (24)
Role of extracorporeal photopheresis in the treatment of cutaneous t‐cell lymphoma, autoimmune disease, and allograft rejection (1994) (23)
The addition of interferon gamma to oral bexarotene therapy with photopheresis for Sézary syndrome. (2005) (23)
Expression of interleukin-4 and interleukin-5 mRNA in developing cutaneous late-phase reactions. (1995) (23)
Malignant and nonmalignant T cell lines from human T cell lymphotropic virus type I-negative patients with Sézary syndrome. (1991) (22)
PREVALENCE, CLINICAL MANIFESTATIONS, AND IMMUNOLOGY OF HERPESVIRUS INFECTIONS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME (1984) (22)
Denileukin diftitox for the treatment of panniculitic lymphoma. (2002) (22)
Progressive epidermotropic CD8+/CD4- primary cutaneous CD30+ lymphoproliferative disorder in a patient with sarcoidosis. (2004) (20)
Photopheresis in the Treatment of Autoimmune Disease: Experience with Pemphigus vulgaris and Systemic Sclerosis (1991) (19)
CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvement. (2008) (19)
Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors (2020) (19)
Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma (2015) (18)
Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma (2011) (18)
The Immunopathogenesis and Immunotherapy of Cutaneous T Cell Lymphoma: Part II, Current and Future Approaches. (2020) (18)
Posttransplantation lymphoproliferative disease with features of lymphomatoid granulomatosis in a lung transplant patient. (2006) (18)
Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy. (2013) (18)
IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome. (2008) (18)
Allogeneic hematopoietic stem cell transplantation for primary cutaneous T cell lymphomas (2011) (18)
Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma. (2002) (17)
The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma. (1998) (17)
The Immunopathogenesis and Immunotherapy of Cutaneous T Cell Lymphoma: Part I, Pathways and Targets for Immune Restoration and Tumor Eradication. (2020) (17)
TIGIT and Helios Are Highly Expressed on CD4+ T Cells in Sézary Syndrome Patients. (2017) (16)
CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214 (2016) (16)
T cell clonality and the effect of photopheresis in systemic sclerosis and graft versus host disease. (2002) (16)
Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. (1998) (16)
Deficient gamma-interferon production in patients with systemic lupus erythematosus. (1986) (16)
Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma. (2002) (15)
Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL): Results from the Phase III MAVORIC Study (2017) (15)
Romidepsin and interferon gamma: a novel combination for refractory cutaneous T-cell lymphoma. (2013) (14)
Vision loss following denileukin diftitox treatment: A case report of possible posterior ischemic optic neuropathy (2007) (14)
A phase I trial of recombinant human interferon-γ in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS) (1989) (14)
Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy (2020) (13)
HTLV-I and CTCL: the link is missing. (1996) (12)
Impaired CD 40 L signaling is a cause of defective IL-12 and TNF-production in Sézary syndrome : circumvention by hexameric soluble CD 40 L (2004) (12)
Romidepsin activity in all three disease compartments (skin, blood, lymph nodes) in patients with cutaneous T-cell lymphoma (CTCL). (2010) (12)
Extracorporeal Photopheresis and Multimodality Immunomodulatory Therapy in the Treatment of Cutaneous T-Cell Lymphoma (2003) (12)
Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab. (2020) (12)
Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor. (2008) (11)
TLR9 Agonist Immunomodulator Treatment of Cutaneous T-Cell Lymphoma (CTCL) with CPG7909. (2004) (11)
Chronic acyclovir-resistant HSV-2 ulcer in an immunosuppressed patient treated with topical cidofovir. (2011) (11)
Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. (2013) (11)
Retroviruses and cutaneous T-cell lymphoma. (1994) (11)
A novel chemotherapeutic regimen (interferon alfa, zidovudine, and etretinate) for adult T-cell lymphoma resulting in rapid tumor destruction. (1999) (11)
Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. (2014) (10)
Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome. (2011) (10)
The importance of cytotoxic cellular immunity in the protection from cytomegalovirus infection. (1984) (10)
Romidepsin (depsipeptide) Induces Clinically Significant Responses in Treatment-Refractory CTCL: An International, Multicenter Study. (2007) (10)
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. (2019) (10)
Dermatologic Events Associated with the Anti-CCR4 Antibody Mogamulizumab: Characterization and Management (2021) (10)
Topical Carmustine as Monotherapy or as Multimodality Therapy for Folliculotropic Mycosis Fungoides. (2017) (9)
CRISPR-Cas9 Knock out of CD5 Enhances the Anti-Tumor Activity of Chimeric Antigen Receptor T Cells (2020) (9)
Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement. (2009) (9)
Importance of Cytotoxic Lymphocytes During Cytomegalovirus Infection in Renal Transplant Recipients (1984) (9)
Progressive multifocal leukoencephalopathy from JC virus in a patient with advanced mycosis fungoides. (2007) (9)
Viral infections and cell-mediated immunity in immunodeficient homosexual men with Kaposi's sarcoma treated with human lymphoblastoid interferon. (1985) (9)
Dysregulation of lymphocyte interleukin-12 receptor expression in Sézary syndrome. (2001) (9)
Mucormycosis in a patient with acquired immunodeficiency syndrome. (1997) (8)
T‐cell receptor gene rearrangement studies as a diagnostic tool in lymphoproliferative skin diseases (1993) (8)
Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. (2009) (8)
Inhibition of cell‐mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T‐cell lymphoma (2012) (8)
Resistance to mogamulizumab is associated with loss of CCR4 in Cutaneous T-cell Lymphoma. (2022) (8)
Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. (2020) (7)
Update on Epidemiology of Cutaneous T-Cell Lymphoma (2013) (7)
Low-dose bexarotene and low-dose interferon alfa-2b for adult T-cell leukemia/lymphoma associated with human T-lymphotropic virus 1. (2005) (7)
New biologic agents for the treatment of cutaneous T-cell lymphoma. (2002) (7)
Progress in immunotherapy of cancer. (2012) (7)
Responses to Romidepsin in Patients with Cutaneous T-Cell Lymphoma (CTCL) and Prior Treatment with Systemic Chemotherapy: Subanalysis from the Pivotal Phase 2 Study (2014) (6)
Cutaneous squamous-cell carcinoma. (2001) (6)
A Single-Arm PHASE 2A Study of NM-IL-12 (rHu-IL12) in Patients with Mycosis Fungoides-Type CTCL (MF) Undergoing Low-Dose TOTAL Skin Electron BEAM Therapy (LD-TSEBT) (2016) (6)
Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children (2013) (6)
EFFECTIVENESS OF PHOTOPHERESIS IN SEZARY SYNDROME. AUTHORS' REPLY (1999) (6)
Photopheresis for scleroderma? Let's abandon the innuendos and get to the data. (1993) (6)
Differential Induction of IL-12 p40 and IL-10 mRNA in Human Langerhans' Cells and Keratinocytes by in Vivo Occlusion, Vehicle, and All-TRANS Retinoic Acid (1996) (6)
Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient. (2003) (5)
Pilot Study of a Novel Therapeutic Approach for Refractory Advanced Stage Folliculotropic Mycosis Fungoides (2020) (5)
Extracorporeal Photopheresis and Multimodality Immunomodulatory Therapy in the Treatment of Cutaneous T-Cell Lymphoma (2003) (5)
CD8+ lymphoma in a patient with human immunodeficiency virus. (2005) (5)
Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis. (2020) (5)
Global Quantitative Techniques for Positron Emission Tomographic Assessment of Disease Activity in Cutaneous T-Cell Lymphoma and Response to Treatment. (2016) (5)
The use of cytokines, fusion proteins and antibodies to treat cutaneous T‐cell lymphoma (2003) (4)
Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) with tumors and/or folliculotropic involvement. (2014) (4)
Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial. (2022) (4)
Extracorporeal photochemotherapy in the treatment of cutaneous T cell lymphoma and autoimmune disorders affecting the skin. (1989) (4)
Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment. (2021) (4)
Use of extracorporeal photochemotherapy in heart transplant recipients during acute rejection: a case study. (1994) (4)
459 Anti-CCR4 monoclonal antibody, mogamulizumab (Moga), demonstrates superior efficacy compared to vorinostat (Vor) in patients with previously treated cutaneous T-cell lymphoma (CTCL): results of the phase 3 MAVORIC study (2018) (4)
Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma. (2011) (4)
Polydactylous Longitudinal Melanonychia Acquired following Total Skin Electron Beam Radiation Therapy for Sézary Syndrome (2015) (3)
Extracorporeal Photopheresis Alone and with Interferon-α2a in Chronic Hepatitis C Patients Who Failed Previous Interferon Therapy (1999) (3)
Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL). (2010) (3)
The beauty of TLR agonists for CTCL. (2012) (3)
B-cell abnormalities in AIDS. (1984) (3)
Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study (2018) (3)
Gain of CD26 expression on the malignant T‐cells in relapsed erythrodermic leukemic mycosis fungoides (2017) (3)
Cytotoxic cellular immunity and cytomegalovirus lessons from studies of the acquired immunodeficiency syndrome and immunosuppressed allograft recipients (1985) (3)
Epigenetic regulation of apoptosis in cutaneous T-cell lymphoma (CTCL): implications for therapy with methotrexate, JAK inhibitors and resveratrol. (2021) (3)
Pembrolizumab in mycosis fungoides and Sézary syndrome: Updated results of the CITN multicenter Phase 2 study (2018) (3)
Therapeutic Advances in Biological Response Modifiers in the Treatment of Cutaneous T-Cell Lymphoma (2012) (3)
Merkel cell polyomavirus in low levels in folliculotropic mycosis fungoides represents a passenger, not a driver (2015) (3)
Rescue photochemotherapy for the treatment of acute cardiac rejection in the absence of cyclosporine maintenance therapy. (1998) (3)
Immune modulators as therapeutic agents for cutaneous T-cell lymphoma. (2010) (3)
Congestive heart failure in a patient with cutaneous T-cell lymphoma treated with low-dose interferon alfa-2b. (2011) (2)
Therapy of Sézary syndrome (2009) (2)
Apoptotic responses to all-trans retinoic acid of targretin-resistant, malignant, CD4+ peripheral blood T cells from patients with Sezary syndrome. (2007) (2)
T Cell Receptor γ-Chain Gene Polymerase Chain Reaction to Diagnose Central Nervous System Involvement by Cutaneous T Cell Lymphoma (2002) (1)
Bexarotene: A Viewpoint by Alain H. Rook, Michael S. Lehrer, Jacqueline M. Junkins-Hopkins, Carmella C. Vittorio, Lars E. French (2000) (1)
Retinoids Synergize with IL‐2 to Increase Interferon‐ γ Production by Peripheral Blood Mononuclear Cells via Induction of IL‐12 (1996) (1)
The relevance of photopheresis to autoreactive diseases. (2012) (1)
Opposing cytokine production by normal Langerhans cells (IL-12) and UV-induced macrophages (IL-10) (1994) (1)
TCRvβ-CART therapy mediates high precision targeting of malignant T-cell clones. (2022) (1)
Usage and safety of topical tacrolimus in patients with mycosis fungoides (2022) (1)
Photoactivated hypericin inhibits proliferation and induces a high rate of apoptotic death of normal and malignant T-lymphocytes from patients with CTCL (1998) (1)
T‐Cell Receptors in Scleroderma Skin The Effect of Photopheresis a (1995) (1)
Imaging Evaluation of Cutaneous Lymphoma Using Functional and Structural Imaging (2016) (1)
Epiproteomic Landscape and Histone Code of Cutaneous T-Cell Lymphoma/Sézary Syndrome (2018) (1)
Cytomegalovirus-specific Cytotoxic Activities of Lymphocytes from Patients with the Acquired Immune Deficiency Syndrome (1983) (0)
lymphoma by CpG oligodeoxynucleotides and IL-15 Enhancement of the host immune responses in cutaneous T-cell (2013) (0)
Th2 cytokine pattern in cutaneous T cell lymphoma correlates with presence of malignant T cell clone: Implications for CTCL etiology, progression, and therapy (1993) (0)
Management of relapsed cutaneous T‐Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case (2022) (0)
How low can you go: quality effects of an anti-CD4 antibody (2007) (0)
Romidepsin in the treatment of hematologic malignancies (2013) (0)
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Interleukin-12 Therapy of Cutaneous T-Cell Lymphoma Induces Lesion Regression and Cytotoxic T-Cell Responses (2016) (0)
Reviewers' list (2005) (0)
Consultations in Molecular Diagnostics T Cell Receptor (cid:1) -Chain Gene Polymerase Chain Reaction to Diagnose Central Nervous System Involvement by Cutaneous T Cell Lymphoma (2002) (0)
Interleukin 2 in vitro corrects the defect in natural killer cell activity in the chediak higashi syndrome (1985) (0)
Apoptosis defects in Sézary syndrome T-cells (2008) (0)
Photopheresis and Systemic Sclerosis-Reply (1992) (0)
Interleukin 12 is safe and effective therapy for cutaneous T-cell lymphoma (1998) (0)
Through Induction of IL-10 Human Peripheral Blood Mononuclear Cells Inhibits Apoptosis in pneumoniaeChlamydia and (2000) (0)
Absence of IL-12 Receptor Sézary Syndrome Is Associated with the Transduction in T Cells from Patients with Depressed IL-12-Mediated Signal (1999) (0)
dendritic cell numbers and the production of cytokines populations: effects of CD40 ligand and treatment with GM-CSF on Sézary syndrome patients demonstrate a defect in dendritic cell (2013) (0)
Extracorporeal Photopheresis in the Treatment of Persistent Rejection in a Pediatric Lung Transplant Recipient (2003) (0)
Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations (2021) (0)
Evaluating Photopheresis Regimens for Advanced CTCL: The Role of the SARS-CoV-2 Pandemic—A Single-Center Retrospective Study (2023) (0)
Paying the Price of Cutaneous T-cell Lymphoma: An analysis of recent trends in skin directed and self-administered systemic treatment costs in the United States for Cutaneous T-cell Lymphoma. (2022) (0)
Where have all the T cells gone (2003) (0)
CD 164 identifies CD 4 + T cells highly expressing genes associated with malignancy in Sézary syndrome : the Sézary signature genes (2019) (0)
Extracorporeal Photopheresis: Principles and Practice (2018) (0)
Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database. (2022) (0)
LB896 Mogamulizumab multimodality therapy with systemic retinoids, interferon, or extracorporeal photopheresis for advanced cutaneous t-cell lymphoma (2022) (0)
Identifying highly active anti-CCR4-CAR T cells for the treatment of T-cell lymphoma. (2023) (0)
Front & Back Matter (2015) (0)
Microbial Response to Carbon Dioxide Injection in a Shallow Aquifer (2007) (0)
T-cell receptor (TCR) beta variable gene (Vβ) expression in mycosis fungoides (MF)/sezary syndrome (SS) defined by automated CDR-3 length spectratyping (1998) (0)
1009 Optimizing immunological reinvigoration in leukemic cutaneous T-cell lymphoma through use of multiple immune checkpoint inhibitors (2019) (0)
The Robust Tumoricidal Effects of Combined BET/HDAC Inhibition in CTCL Can Be Reproduced by ΔNp73 Depletion. (2022) (0)
Interferon-Related Leukocyte Inclusions in Acquired Immune Deficiency Syndrome: Localization in T Cells (1984) (0)
Unique Characteristics of Classical Hodgkin Lymphoma in Patients with Cutaneous T-Cell Lymphoma (2015) (0)
Primary cutaneous lymphoma: FDG-PET/CT and its potential applications in monitoring response to treatment (2013) (0)
Interleukin-18 (IL-18) and interleukin-12 (IL-12) synergistically augment cell-mediated immunity in cutaneous T-cell lymphoma (CTCL) (1998) (0)
TCF1 and Tox define different subsets of CD4 T cells in patients with Sézary syndrome (2022) (0)
99% circulating tumor cells with 90% accuracy Quantitative PCR on 5 genes reliably identifies CTCL patients with 5% to (2013) (0)
OBSERVATION CD 8 Epidermotropic Cytotoxic T-Cell Lymphoma With Peripheral Blood and Central Nervous System Involvement (2008) (0)
T cell receptor gamma-chain gene polymerase chain reaction to diagnose central nervous system involvement by cutaneous T cell lymphoma. (2002) (0)
Author index (2005) (0)
Amendment history : Corrigendum ( March 2007 ) Immunopathogenesis and therapy of cutaneous T cell lymphoma (2018) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alain H. Rook?

Alain H. Rook is affiliated with the following schools:

Yale University
University of Michigan
Uniformed Services University of the Health Sciences
University of Pennsylvania

Alain H. Rook's Academic­Influence.com Rankings

Why Is Alain H. Rook Influential?

Alain H. Rook's Published Works

Published Works

What Schools Are Affiliated With Alain H. Rook?

Alain H. Rook's AcademicInfluence.com Rankings